CVKD · Cadrenal Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $771.5K | - | $688.5K | $1.08M | $1.67M | - | $784.6K | $1.25M | $629.0K | - |
| SG&A | $1.74M | - | $2.04M | $2.66M | $2.25M | - | $1.67M | $1.21M | $1.13M | - |
| Total Operating Expenses | $2.51M | - | $2.73M | $3.73M | $3.93M | - | $2.46M | $2.47M | $1.76M | - |
| D&A | $555 | - | $401 | $401 | $5.5K | - | $407 | $470 | $597 | - |
| Operating Income | ($2.51M) | - | ($2.73M) | ($3.73M) | ($3.93M) | - | ($2.46M) | ($2.47M) | ($1.76M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.50M) | - | ($2.69M) | ($3.67M) | ($3.85M) | - | ($2.41M) | ($2.39M) | ($1.66M) | - |
| EPS - Basic | ($1.04) | - | ($1.31) | ($1.87) | ($2.09) | - | ($2.18) | ($2.25) | ($1.50) | - |
| EPS - Diluted | ($1.04) | - | ($1.31) | ($1.87) | ($2.09) | - | ($2.18) | ($2.25) | ($1.50) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.31M | $4.01M | $3.86M | $5.00M | $7.34M | $10.00M | $4.36M | $5.04M | $6.57M | $8.40M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $824.8K | $650.7K | $614.1K | $895.6K | $1.28M | $1.50M | $496.8K | $759.5K | $400.4K | $167.3K |
| Current Assets | $2.86M | $4.32M | $4.08M | $5.97M | $7.94M | $10.11M | $4.67M | $5.44M | $7.03M | $8.49M |
| Total Assets | $2.86M | $4.33M | $4.09M | $5.98M | $7.95M | $10.12M | $4.68M | $5.46M | $7.05M | $8.52M |
| Current Liabilities | $1.06M | $1.59M | $1.35M | $1.68M | $1.84M | $2.68M | $1.27M | $1.46M | $856.3K | $826.9K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.06M | $1.59M | $1.35M | $1.68M | $1.84M | $2.68M | $1.27M | $1.46M | $856.3K | $826.9K |
| Stockholders' Equity | $1.80M | $2.74M | $2.73M | $4.30M | $6.11M | $7.44M | $3.41M | $3.99M | $6.19M | $7.69M |
| Retained Earnings | ($41.46M) | ($38.96M) | ($35.92M) | ($33.24M) | ($29.57M) | ($25.72M) | ($21.54M) | ($19.13M) | ($16.73M) | ($15.07M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.00M) | - | - | - | ($4.65M) | - | - | - | ($1.84M) | - |
| Investing Cash Flow | - | - | - | - | ($3.3K) | - | - | - | - | - |
| Financing Cash Flow | $1.30M | - | - | - | $1.97M | - | - | - | $298 | - |
| CapEx | - | - | - | - | $3.3K | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | ($4.65M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 1.21 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -87.2% | - | -65.7% | -61.3% | -48.3% | - | -51.5% | -43.9% | -23.6% | - |
| Return on equity | -138.9% | - | -98.2% | -85.3% | -62.9% | - | -70.6% | -59.9% | -26.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.68 | 2.72 | 3.02 | 3.56 | 4.32 | 3.77 | 3.69 | 3.72 | 8.21 | 10.27 |
| Quick ratio | 2.68 | 2.72 | 3.02 | 3.56 | 4.32 | 3.77 | 3.69 | 3.72 | 8.21 | 10.27 |
| Cash ratio | 2.17 | 2.52 | 2.85 | 2.98 | 3.99 | 3.73 | 3.44 | 3.44 | 7.67 | 10.16 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.59 | 1.58 | 1.49 | 1.39 | 1.30 | 1.36 | 1.37 | 1.37 | 1.14 | 1.11 |
| Liabilities / Assets | 0.37 | 0.37 | 0.33 | 0.28 | 0.23 | 0.27 | 0.27 | 0.27 | 0.12 | 0.10 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 6.9x | - | 10.3x | 5.0x | 5.3x | - | 4.4x | 28.3x | 23.7x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 36.0% | - | -11.1% | -51.4% | -123.7% | - | -115.3% | -140.4% | 58.2% | - |
| Net income growth (YoY) | 35.1% | - | -11.5% | -53.3% | -131.2% | - | -134.7% | -138.6% | 67.9% | - |
| EPS growth (YoY) | 50.2% | - | 39.9% | 16.9% | -39.3% | - | -3014.3% | -2400.0% | -212.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -70.6% | -63.2% | -19.9% | 7.7% | -1.3% | -3.3% | - | - | 52.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$200.00M totalRoyalty$200.00M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Cadrenal Therapeutics against the 5 most active filers in the same SIC group.